ArticleEcho research and practice2026
Multi-valvular burden score and one-year mortality in ICU patients undergoing echocardiography: an exploratory cohort study.
Article in Echo research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple regurgitant lesions coexist in critically ill patients, yet cohort-level analyses typically represent each valve separately. We evaluated whether a Multi-Valvular Burden (MVB) score could summarize regurgitant involvement and whether its prognostic information differed from models retaining individual valve grades.
methodsThis retrospective cohort used MIMIC-IV v3.1 linked with MIMIC-IV-ECHO. Adults with an ICU admission and complete ordinal grading of tricuspid, mitral, and aortic regurgitation on an index echocardiogram within 72 h of ICU admission were included. MVB was the arithmetic sum of TR, MR, and AR grades (0-12). Cox models assessed 1-year all-cause mortality. Additional analyses compared MVB with separate valve-grade models, tested a high-burden definition requiring MVB > = 4 and at least two involved valves, used missing-aware AS/MS evidence proxies, and examined LVEF with structured RV-function classification.
resultsThe cohort included 5,362 patients; 1,979 (36.9%) died within 1 year. Mortality increased from 24.6% at MVB 0 to 47.4% at MVB > = 4. After clinical adjustment, continuous MVB remained associated with mortality (HR 1.07 per point, 95% CI 1.05-1.09; P < 0.001), and MVB > = 4 was associated with higher mortality (HR 1.35, 95% CI 1.22-1.48; P < 0.001). The high-burden category predominantly reflected multivalve involvement: 2,206 of 2,257 patients with MVB > = 4 had at least two affected valves. A model with separate TR, MR, and AR grades showed similar discrimination to the MVB model (C-index 0.7585 vs. 0.7582). Incremental discrimination over the clinical model was small (C-index 0.7543 to 0.7582; delta 0.0039), although likelihood-ratio improvement was statistically significant (chi-square 50.61; P < 0.001). MVB remained associated with mortality in the missing-aware AS/MS sensitivity model (HR 1.07, 95% CI 1.05-1.09) and the LVEF/structured RV-function subset (HR 1.05, 95% CI 1.03-1.08).
conclusionsMVB is an exploratory summary marker rather than an outcome-derived or mechanistic weighting system. Its near-identical discrimination to a model retaining individual valve grades and very modest incremental discrimination suggest that it is best viewed as a compact descriptive marker of broader cardiovascular burden within systemic critical illness, not as a stand-alone clinical decision tool or evidence of a causal pathway to mortality. CLINICAL TRIAL NUMBER: Not applicable.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.